Dr. Julian Dopstadt is Director of ADME at Eli Lilly and Company, where he supports drug discovery and development across all disease areas and modalities. With over 8 years of experience in the field at leading pharma companies in Europe and the US, he brings deep expertise in biotransformation and covalent drug discovery & development. Julian proposed, initiated, and chaired the IQ Consortium Working Group on Targeted Covalent Inhibitors, reflecting his commitment to advancing industry-wide best practices.